Australija - anglų - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium chloride, quantity: 2.92 g/l; potassium chloride, quantity: 7.46 g/l - injection, intravenous infusion - excipient ingredients: water for injections - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - olive oil, quantity: 50 g; fish oil - rich in omega-3 acids, quantity: 30 g; medium chain triglycerides, quantity: 60 g; soya oil, quantity: 60 g - injection, intravenous infusion - excipient ingredients: glycerol; sodium oleate; dl-alpha-tocopherol; water for injections; egg lecithin; sodium hydroxide - supply of energy and essential fatty acids to patients, as part of a parenteral nutrition regimen, when oral or enteral nutrition is impossible, insufficient or contra-indicated.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

alexion pharmaceuticals australasia pty ltd - eculizumab, quantity: 300 mg - injection, intravenous infusion - excipient ingredients: polysorbate 80; sodium chloride; water for injections; dibasic sodium phosphate heptahydrate; monobasic sodium phosphate monohydrate - soliris is indicated for the treatment of patients with: ? paroxysmal nocturnal haemoglobinuria (pnh) to reduce haemolysis. ? atypical haemolytic uraemic syndrome (ahus). ? adult patients with neuromyelitis optica spectrum disorder (nmosd) who are anti-aquaporin-4 (aqp4) antibody-positive. soliris is not intended for acute treatment of a nmosd relapse.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ciprofloxacin, quantity: 100 mg - injection, solution - excipient ingredients: lactic acid; hydrochloric acid; water for injections; glucose monohydrate - ciprofloxacin injection for intravenous infusion is indicated for use in the following: 1. hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. 2. for the treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems: - lower respiratory tract infections (gram-negative organisms). skin and skin structure. septicaemia. bone and joint. urinary tract. 3. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram positive infections due to streptococcus pneumoniae. if anaerobic organisms are suspected of contributing to the infection, use of other suitable drugs should be considered. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiologic agents, additional therapy should be considered.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - glucose monohydrate, quantity: 55 g/l - injection, intravenous infusion - excipient ingredients: water for injections - for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. may also be used as solvents for intravenously administered drugs where compatibility has been established.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - glucose monohydrate, quantity: 55 g/l - injection, intravenous infusion - excipient ingredients: water for injections - for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. may also be used as solvents for intravenously administered drugs where compatibility has been established.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: water for injections - for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. may also be used as solvents for intravenously administered drugs where compatibility has been established. may also be used for irrigation of wounds and moistening of wound dressings.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: water for injections - for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. may also be used as solvents for intravenously administered drugs where compatibility has been established. may also be used for irrigation of wounds and moistening of wound dressings.

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

bayer plc - levonorgestrel - intrauterine device - 13.5mg

Australija - anglų - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - aciclovir, quantity: 25 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections - aciclovir intravenous infusion is indicated for the purpose of 1. promoting resolution of acute clinical manifestations of mucocutaneous herpes simplex virus infections in immunocompromised patients. 2. treatment of severe first episode primary or non- primary genital herpes in immune competent patients. 3. treatment of acute manifestations of varicella zoster virus infection in immunocompromised patients. 4. treatment of shingles (varicella zoster virus infection) in immune competent patients who show very severe acute local or systemic manifestations of the disease. benefits can be expected in patients with rash duration shorter than 72 hours. the use of the intravenous infusion may be warranted in only a small subgroup of immune competent patients with shingles. 5. treatment of herpes simplex encephalitis.